HEM On Other Exchanges
Symbol
Exchange
Venture
OTC US
OTC US
Toronto
Frankfurt

hemostemix inc (HEM) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
--
EPS TTM
--
Shares Outstanding
--
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HEMOSTEMIX INC (HEM)
\

Related News

No related news articles were found.

hemostemix inc (HEM) Related Businessweek News

No Related Businessweek News Found

hemostemix inc (HEM) Details

Hemostemix Inc., a clinical-stage biotechnology company, develops, manufactures, and commercializes blood-derived cell therapies for medical conditions in Canada. It develops cell therapy products from the patient’s own blood, a relatively non-invasive source of therapeutic cells. The company’s lead product is ACP-01, which is in Phase II clinical trial for the treatment of critical limb ischemia. It is also developing various types of cells products, such as synergetic cell precursors, myocardial cell precursors, and neural cell precursors. Hemostemix Inc. is headquartered in Calgary, Canada.

hemostemix inc (HEM) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: C$105.8K
Compensation as of Fiscal Year 2017.
hemostemix inc
Hemostemix Inc. Presents at 2019 BIO International Conference, Jun-05-2019 01:30 PM

Hemostemix Inc. Presents at 2019 BIO International Conference, Jun-05-2019 01:30 PM. Venue: Pennsylvania Convention Center, Philadelphia, Pennsylvania, United States. Speakers: Alan J. Jacobs, President & Chief Medical Officer.

Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2018

Hemostemix Inc. announced earnings results for the full year ended December 31, 2018. For the full year, the company announced net loss was CAD 6.187 million compared to CAD 3.934 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.02 a year ago.

Hemostemix Inc. Auditor Raises 'Going Concern' Doubt

Hemostemix Inc. filed its Annual on Apr 30, 2019 for the period ending Dec 31, 2018. In this report its auditor, Meyers Norris Penny LLP - MNP LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

HEM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for HEM.
View Industry Companies
 

Industry Analysis

HEM

Industry Average

Valuation HEM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact HEMOSTEMIX INC, please visit www.hemostemix.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.